Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Fluticasone Furoate NS/Fluticasone Propionate NS	Participants who received Fluticasone Furoate Nasal Spray (FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.
Placebo - FF/FP	Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.
Fluticasone Propionate NS/Fluticasone Furoate NS	Participants who received Fluticasone Propionate Nasal Spray (FPNS)110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.
Placebo - FP/FF	Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.

Participant Flow for 5 periods

	Fluticasone Furoate NS/Fluticasone Propionate NS	Placebo - FF/FP	Fluticasone Propionate NS/Fluticasone Furoate NS	Placebo - FP/FF
STARTED	96	95	95	91
COMPLETED	96	94	95	91
NOT COMPLETED	0	1	0	0
Unknown	0	1	0	0

	Fluticasone Furoate NS/Fluticasone Propionate NS	Placebo - FF/FP	Fluticasone Propionate NS/Fluticasone Furoate NS	Placebo - FP/FF
STARTED	96	94	95	91
COMPLETED	96	94	93	90
NOT COMPLETED	0	0	2	1
Lost to Follow-up	0	0	1	0
Protocol Violation	0	0	1	0
Lack of Efficacy	0	0	0	1

	Fluticasone Furoate NS/Fluticasone Propionate NS	Placebo - FF/FP	Fluticasone Propionate NS/Fluticasone Furoate NS	Placebo - FP/FF
STARTED	96	94	93	90
COMPLETED	76	84	77	81
NOT COMPLETED	20	10	16	9
Adverse Event	2	1	0	0
Protocol Violation	1	1	0	0
Withdrawal by Subject	0	2	0	0
Failed to meet continuation criteria	16	5	14	6
Unknown	1	1	2	3

	Fluticasone Furoate NS/Fluticasone Propionate NS	Placebo - FF/FP	Fluticasone Propionate NS/Fluticasone Furoate NS	Placebo - FP/FF
STARTED	76	84	77	81
COMPLETED	75	83	77	81
NOT COMPLETED	1	1	0	0
Protocol Violation	1	0	0	0
Unknown	0	1	0	0

	Fluticasone Furoate NS/Fluticasone Propionate NS	Placebo - FF/FP	Fluticasone Propionate NS/Fluticasone Furoate NS	Placebo - FP/FF
STARTED	75	83	77	81
COMPLETED	75	83	77	81
NOT COMPLETED	0	0	0	0

Reporting Groups

	Description
Fluticasone Furoate NS/Fluticasone Propionate NS	Participants who received Fluticasone Furoate Nasal Spray (FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.
Placebo - FF/FP	Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.
Fluticasone Propionate NS/Fluticasone Furoate NS	Participants who received Fluticasone Propionate Nasal Spray (FPNS)110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.
Placebo - FP/FF	Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.

Baseline Measures

	Fluticasone Furoate NS/Fluticasone Propionate NS	Placebo - FF/FP	Fluticasone Propionate NS/Fluticasone Furoate NS	Placebo - FP/FF	Total
Number of Participants   [units: participants]	96	95	95	91	377
Age   [units: years] Mean ± Standard Deviation	37.3 ± 13.89	42 ± 12.48	40.5 ± 12.29	39.7 ± 14.32	39.9 ± 13.33
Gender   [units: participants]
Female	62	73	67	60	262
Male	34	22	28	31	115
Race/Ethnicity, Customized   [units: participants]
American/African Heritage	8	8	10	8	34
American Indian or Alaska Native	0	0	0	0	0
Asian	0	3	1	1	5
Native Hawaiian or other Pacific Islander	0	0	1	0	1
White	88	84	82	80	334
African American/African-American Indian/Alaskan	0	0	0	1	1
African American/African Heritage & White	0	0	1	1	2

1.  Primary:

Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos   [ Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21) ]

2.  Primary:

Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor   [ End of Crossover Period (Day 22) ]

3.  Secondary:

Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat   [ End of Crossover Period (Day 22) ]

4.  Secondary:

Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use   [ End of Crossover Period (Day 22) ]

5.  Secondary:

Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist   [ End of Crossover Period (Day 22) ]

6.  Secondary:

Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos   [ Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21) ]

7.  Secondary:

Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos   [ Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21) ]